ABOUT
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The company’s wholly owned, clinical-stage subsidiary, OnkosXcel Therapeutics, is focused on developing medicines in immuno-oncology.
Innovating Medicine by Leveraging Artificial Intelligence
Innovating Medicine by Leveraging Artificial Intelligence
Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.
Therapeutic Area Focus
Targeting neuroscience disorders with significant unmet medical needs and large market opportunities
Drug Re-Innovation
Higher Probability of Success
Therapeutic Benefit
Potential to provide clinical benefit to patients in need
Our Differentiated Approach
Our Differentiated Approach
Therapeutic Area Focus
Targeting neuroscience disorders and immuno-oncology with significant unmet medical need and large market opportunity
Drug Re-Innovation
The proprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidates
Higher Probability of Success
Therapeutic Benefit
Potential to provide clinical benefit to patients in need
